S. Oghina

发表

Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment

E. Teiger, L. Hittinger, F. Montestruc, 2021, Journal of clinical medicine.

Evaluation of a new ELISA assay for monoclonal free‐light chain detection in patients with cardiac amyloidosis

A. Maarek, A. Moktefi, T. Damy, 2022, EJHaem.

History of extracardiac/cardiac events in cardiac amyloidosis: prevalence and time from initial onset to diagnosis

J. Deux, J. Lefaucheur, F. Lemonnier, 2021, ESC heart failure.

Natural history and impact of treatment with tafamidis on major cardiovascular outcome‐free survival time in a cohort of patients with transthyretin amyloidosis

J. Deux, J. Lefaucheur, E. Teiger, 2020, European journal of heart failure.

Prevalence and prognostic value of autonomic neuropathy assessed by Sudoscan® in transthyretin wild‐type cardiac amyloidosis

J. Lefaucheur, F. Roche, E. Teiger, 2020, ESC heart failure.

Describing mode of death in three major cardiac amyloidosis subtypes to improve management and survival

A. Amiot, J. Deux, E. Teiger, 2022, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

Electrical cardioversion of atrial arrhythmias with cardiac amyloidosis in the era of direct oral anticogulants

É. Marijon, E. Teiger, V. Algalarrondo, 2022, ESC heart failure.

Echocardiographic Patterns of Left Ventricular Diastolic Function in Cardiac Amyloidosis: An Updated Evaluation

J. Deux, E. Teiger, E. Itti, 2021, Journal of clinical medicine.

Extracardiac soft tissue uptake, evidenced on early 99mTc-HMDP SPECT/CT, helps typing cardiac amyloidosis and demonstrates high prognostic value

J. Deux, J. Lefaucheur, E. Itti, 2020, European Journal of Nuclear Medicine and Molecular Imaging.

AA amyloidosis complicating monoclonal gammopathies, an unusual feature validating the concept of “monoclonal gammopathy of inflammatory significance”?

J. Boffa, S. Georgin-lavialle, A. Jaccard, 2021, International journal of clinical practice.

Tafamidis Decreases Cardiac Uptake of 99mTc-HMDP in Transthyretin Cardiac Amyloidosis.

E. Teiger, E. Itti, T. Damy, 2022, JACC. Cardiovascular imaging.

Natural course and determinants of short-term kidney function decline in hereditary transthyretin amyloidosis: a French observational study

A. Moktefi, P. Grimbert, P. Rémy, 2022, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

The Impact of Patients With Cardiac Amyloidosis in HFpEF Trials.

A. Cohen-Solal, A. Mebazaa, M. Komajda, 2021, JACC. Heart failure.

Dexamethasone is associated with early deaths in light chain amyloidosis patients with severe cardiac involvement

F. Lemonnier, E. Teiger, O. Agbulut, 2021, PloS one.

Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms

C. Rapezzi, M. Maurer, A. Dispenzieri, 2022, JACC. CardioOncology.

Prevalence and determinants of iron deficiency in cardiac amyloidosis

E. Teiger, L. Hittinger, B. Funalot, 2022, ESC heart failure.

Assessing Cardiac Amyloidosis Subtypes by Unsupervised Phenotype Clustering Analysis.

J. Deux, E. Audureau, E. Itti, 2021, Journal of the American College of Cardiology.

Frailty in Wild-Type Transthyretin Cardiac Amyloidosis: The Tip of the Iceberg

E. Teiger, S. Bastuji‐Garin, T. Damy, 2021, Journal of clinical medicine.

Amylo-AFFECT-QOL, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis

A. Amiot, J. Lefaucheur, E. Audureau, 2023, Frontiers in Cardiovascular Medicine.

Daratumumab is safe and induces a rapid hematological response in light-chain amyloidosis with severe cardiac impairment

F. Lemonnier, C. Haioun, A. Maarek, 2020, Leukemia & lymphoma.

Real-Life Evaluation of an Algorithm for the Diagnosis of Cardiac Amyloidosis.

J. Deux, E. Teiger, L. Hittinger, 2022, Mayo Clinic proceedings.

Venetoclax induces sustained complete responses in refractory/relapsed patients with cardiac AL amyloidosis.

F. Lemonnier, C. Haioun, A. Maarek, 2019, Journal of Clinical Oncology.

Heart Transplantation, Either Alone or Combined With Liver and Kidney, a Viable Treatment Option for Selected Patients With Severe Cardiac Amyloidosis

A. De la taille, C. Duvoux, E. Teiger, 2022, Transplantation direct.

Comparison of cardiac involvement, extracardiac manifestations and outcomes between homozygote and heterozygote transthyretin p.Val142Ile (V122I) variant in patients with hereditary transthyretin amyloidosis: a cohort study

E. Teiger, L. Hittinger, B. Funalot, 2023, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[Cardiac amyloidosis: State of art in 2022].

T. Damy, P. Fanen, S. Oghina, 2022, La Revue de medecine interne.

Prevalence, Characteristics, and Impact on Prognosis of Aortic Stenosis in Patients With Cardiac Amyloidosis

R. Carter-Storch, M. Annabi, M. Kharoubi, 2024, Journal of the American Heart Association.

Phenotype and prognostic factors in geriatric and non-geriatric patients with transthyretin cardiomyopathy.

V. Planté-Bordeneuve, M. Kharoubi, A. Zaroui, 2024, ESC heart failure.

Frailty in heart failure according to the presence or absence of wild-type transthyretin cardiac amyloidosis.

M. Kharoubi, A. Zaroui, A. Galat, 2024, ESC heart failure.